Argenx SE FY25 swings to profit as Vyvgart sales double
#Argenx SE #Vyvgart #FY25 Profit #Autoimmune Drug #Immunology #Financial Results #Phase 3 Trials #Ocular Myasthenia Gravis
📌 Key Takeaways
- Argenx achieved its first full-year operating profit in FY25, reporting $1.05 billion in operating income
- Vyvgart sales more than doubled, driving 90% increase in full-year product net sales to $4.15 billion
- The company reached 19,000 patients globally with Vyvgart during 2025
- Net profit rose to $1.29 billion, primarily driven by commercial operations rather than tax benefits
- Positive Phase 3 results for Vyvgart in ocular myasthenia gravis position the company for future expansion
📖 Full Retelling
Argenx SE, a Belgian immunology company, announced on Thursday, February 26, 2026, that it had achieved its first full-year operating profit, reporting $1.05 billion in operating income for FY25, a dramatic turnaround from the $21.7 million loss recorded in the previous year. This impressive financial performance was primarily driven by the more than doubling of sales for its flagship autoimmune drug Vyvgart, which helped the company reach 19,000 patients globally during 2025. The company's full-year product net sales surged 90% to $4.15 billion, up from $2.19 billion in 2024, with fourth-quarter sales alone reaching $1.29 billion compared to $737 million in the same period a year earlier. Net profit for 2025 rose to $1.29 billion from $833 million in 2024, though the prior-year figure was significantly boosted by a $748 million deferred tax benefit. Notably, the 2025 net profit was supported by only $13 million in net tax benefit, marking the first year that earnings were primarily driven by commercial operations rather than one-time tax benefits. Basic profit per share increased to $21.08 from $13.92 in 2024. Looking ahead, argenx reported positive topline results from the Phase 3 ADAPT OCULUS study of Vyvgart subcutaneous pre-filled syringe in ocular myasthenia gravis, with plans to submit a supplemental biologics license application to expand the drug's label. The company expects topline results for primary immune thrombocytopenia from the ADVANCE-NEXT study in Q4 2026, with additional studies ongoing in autoimmune inflammatory myopathies and Sjogren's disease.
🏷️ Themes
Financial Performance, Pharmaceutical Innovation, Market Expansion
📚 Related People & Topics
Efgartigimod alfa
Medication
Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis. Efgartigimod alfa is a neonatal Fc receptor blocker and is a new class of medication. It is an antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immuno...
Immunology
Branch of medicine studying the immune system
Immunology is a branch of biology and medicine that covers the study of immune systems in all organisms. Immunology charts, measures, and contextualizes the physiological functioning of the immune system in states of both health and diseases; malfunctions of the immune system in immunological disord...
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Nvidia’s results beat estimates, but Wall Street wants more cash return Gold ticks up on softer dollar, markets eye US-Iran nuclear talks Nasdaq ends more than 1% higher as Nvidia rises pre-earnings, tech extends rebound Nvidia set to report strong results and guidance, analysts say (South Africa Philippines Nigeria) Argenx SE FY25 swings to profit as Vyvgart sales double By Navamya Acharya Author Navamya Acharya Earnings Published 02/26/2026, 03:15 AM Argenx SE FY25 swings to profit as Vyvgart sales double 0 ARGX 2.14% Investing.com -- Belgian immunology company argenx SE posted its first full-year operating profit on Thursday, swinging to $1.05 billion in operating income in 2025 from a $21.7 million loss a year earlier, as sales of its autoimmune drug Vyvgart more than doubled. Full-year product net sales rose 90% to $4.15 billion from $2.19 billion in 2024, with fourth-quarter sales reaching $1.29 billion versus $737 million in the same period a year earlier. The company reached 19,000 patients globally with Vyvgart during the year. Track breaking market moves with live headlines and analyst notes - up to 50% off Net profit for 2025 rose to $1.29 billion from $833 million in 2024, though the prior-year figure was heavily supported by a $748 million deferred tax benefit. The 2025 net profit was underpinned by just $13 million in net tax benefit, making it the first year in which earnings were driven primarily by commercial operations. Basic profit per share rose to $21.08 from $13.92 in 2024. "argenx delivered another standout year of execution in 2025," chief executive Tim Van Hauwermeiren said in a statement. "We reached 19,000 patients globally with Vyvgart, expanded our impact across gMG and CIDP through the successful launch of the pre-filled syringe, and made substantial progress across our development programs." Total operating expenses rose to $3.19 billion in 2025 from $2.27 billion in 2024. Resea...
Read full article at source